Achievement of Precision Medicine for AMD by Treatment Regimen Comparison and Genetic Analysis

Achievement of Precision Medicine for AMD by Treatment Regimen Comparison and Genetic Analysis - PREARRANGE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028002

Enrollment

500

Registered

2017-07-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration

Interventions

Aflibercept 2mg (PRN regimen), 24 months period Aflibercept 2mg (TAE regimen), 24 months period

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Treatment-naive neovasucular age-related macular degeneration Best corrected visual acuity of 0.05-0.8 Eyes without subfoveal fibrosis

Exclusion criteria

Exclusion criteria: Prior vitrectomy Rupture of posterior lens capsule Cataract surgery within 3 months Angioid Streaks Myopic chodoidal neovascularization Vitelliform macular dystrophy

Design outcomes

Primary

Measure	Time frame
Visual acuity change at 12th month	—

Secondary

Measure	Time frame
Visual acuity change at 24th month Visual acuity at 12th month Visual acuity at 24th month Number of injections during 12 months Number of injections during 24 months Genes associted with visual acuity, visual acuity change, and number of injections Genes associted with outcome of loading treatment, appropriate interval of injection for each patient	—

Countries

Japan

Contacts

Public ContactKenji Yamashiro

Kyoto University Graduate School of Medicine Ophthalmology and Visual Sciences

yamashro@kuhp.kyoto-u.ac.jp+81-75-751-3248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026